New hope for gene therapy approval as AMT files Glybera in EU
This article was originally published in Scrip
Executive Summary
Amsterdam Molecular Therapeutics has filed its only drug candidate – Glybera (lipoprotein lipase gene therapy) for the rare genetic disease lipoprotein lipase deficiency (LPLD) – with the EMA, hoping that it could become the first gene therapy to be approved in the EU.